Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | CNR2 | P34972 | 3/20 | 0.31 |
| ▸ | CNR1 | P21554 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2077350 | 0.99 | ALDH1A1 (0.41) | ALDH1A1SMN1; SMN2CNR2CNR1CYP19A1 | |
| SCHEMBL2077662 | 0.96 | ALDH1A1 (0.43) | ALDH1A1SMN1; SMN2MAPTL3MBTL1CYP19A1 | |
| SCHEMBL2076095 | 0.91 | ALDH1A1 (0.44) | ALDH1A1MAPTL3MBTL1CYP19A1 | |
| SCHEMBL2077395 | 0.86 | ALDH1A1 (0.47) | ALDH1A1MAPTL3MBTL1CYP19A1 | |
| SCHEMBL2076065 | 0.80 | ALDH1A1 (0.43) | ALDH1A1MAPTL3MBTL1CYP19A1 | |
| SCHEMBL2077348 | 0.78 | ALDH1A1 (0.49) | ALDH1A1SMN1; SMN2MAPTL3MBTL1CYP19A1 | |
| SCHEMBL16369585 | 0.76 | ALDH1A1 (0.42) | ALDH1A1SMN1; SMN2MAPT | |
| SCHEMBL2077889 | 0.76 | ALDH1A1 (0.47) | ALDH1A1MAPTL3MBTL1CYP19A1 | |
| SCHEMBL2077429 | 0.75 | ALDH1A1 (0.43) | ALDH1A1MAPTL3MBTL1CYP19A1 | |
| SCHEMBL2075030 | 0.74 | ALDH1A1 (0.46) | ALDH1A1MAPTL3MBTL1CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2028183-B1 | NOVEL EPOXY COMPOUND AND METHOD FOR PRODUCING THE SAME | SHOWA DENKO KK (JP) | 2014-03-26 | — | — | EP | disclosed |
| US-7863461-B2 | Epoxy compounds and method for production of the same | SHOWA DENKO K.K. (JP) | 2011-01-04 | — | — | US | disclosed |
| US-20090253915-A1 | NOVEL EPOXY COMPOUNDS AND METHOD FOR PRODUCTION OF THE SAME | SHOWA DENKO K.K. (JP) | 2009-10-08 | — | — | US | disclosed |
| EP-2028183-A1 | NOVEL EPOXY COMPOUND AND METHOD FOR PRODUCING THE SAME | Showa Denko K.K. (JP) | 2009-02-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090253915-A1 | NOVEL EPOXY COMPOUNDS AND METHOD FOR PRODUCTION OF THE SAME | PTGIS, PTGES, CYP2E1 | ALDH1A1 607/4885SMN1; SMN2 4382/4885CNR2 1641/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.